163P Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma: An interim analysis of the prospective, single-arm, phase II trial. (December 2022) - Yang, J.; Zhang, Z.; Wu, B.; Qin, Y.; Wei, J.; Qu, Y.; Sun, Q.; Jiang, K.; Yang, K.